Switch theme
Sign up to access all valuation multiples
Alto Neuroscience Inc is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individuals’ neurobiology to develop personalized and effective treatment options. The company currently consists of different clinical-stage assets such as ALTO-100, ALTO-202, ALTO-101, and ALTO-300 among others initially targeting depressive disorders and schizophrenia populations as identified by independent brain-based biomarkers.
2019
76
LTM Revenue n/a
LTM EBITDA -$73.0M
-$95.0M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Alto Neuroscience has a last 12-month revenue of n/a and a last 12-month EBITDA of -$73.0M.
In the most recent fiscal year, Alto Neuroscience achieved revenue of n/a and an EBITDA of -$59.6M.
Alto Neuroscience expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Alto Neuroscience valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | n/a | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | n/a | XXX | XXX | XXX |
| Gross Margin | NaN% | NaN% | XXX | XXX | XXX |
| EBITDA | -$34.6M | -$59.6M | XXX | XXX | XXX |
| EBITDA Margin | -Infinity% | -Infinity% | XXX | XXX | XXX |
| Net Profit | -$27.7M | -$36.3M | XXX | XXX | XXX |
| Net Margin | -Infinity% | -Infinity% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Alto Neuroscience's stock price is $2.
Alto Neuroscience has current market cap of $56.3M, and EV of -$95.0M.
See Alto Neuroscience trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$95.0M | $56.3M | XXX | XXX | XXX | XXX | $-2.53 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Alto Neuroscience has market cap of $56.3M and EV of -$95.0M.
Alto Neuroscience's trades at n/a LTM EV/Revenue multiple, and 1.3x LTM EBITDA.
Analysts estimate Alto Neuroscience's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Alto Neuroscience and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | -$95.0M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | XXX | XXX |
| EV/EBITDA | 1.6x | XXX | XXX | XXX |
| P/E | -0.9x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | 1.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpAlto Neuroscience's NTM/LTM revenue growth is n/a
Alto Neuroscience's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $0.9M for the same period.
Over next 12 months, Alto Neuroscience's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Alto Neuroscience's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Alto Neuroscience and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | XXX | XXX | XXX |
| EBITDA Growth | 72% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.9M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | n/a | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Alto Neuroscience acquired XXX companies to date.
Last acquisition by Alto Neuroscience was XXXXXXXX, XXXXX XXXXX XXXXXX . Alto Neuroscience acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Alto Neuroscience founded? | Alto Neuroscience was founded in 2019. |
| Where is Alto Neuroscience headquartered? | Alto Neuroscience is headquartered in United States of America. |
| How many employees does Alto Neuroscience have? | As of today, Alto Neuroscience has 76 employees. |
| Who is the CEO of Alto Neuroscience? | Alto Neuroscience's CEO is Dr. Amit Etkin, M.D.. |
| Is Alto Neuroscience publicy listed? | Yes, Alto Neuroscience is a public company listed on NYS. |
| What is the stock symbol of Alto Neuroscience? | Alto Neuroscience trades under ANRO ticker. |
| When did Alto Neuroscience go public? | Alto Neuroscience went public in 2024. |
| Who are competitors of Alto Neuroscience? | Similar companies to Alto Neuroscience include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Alto Neuroscience? | Alto Neuroscience's current market cap is $56.3M |
| What is the current EBITDA of Alto Neuroscience? | Alto Neuroscience's last 12-month EBITDA is -$73.0M. |
| What is the current EV/EBITDA multiple of Alto Neuroscience? | Current EBITDA multiple of Alto Neuroscience is 1.3x. |
| Is Alto Neuroscience profitable? | Yes, Alto Neuroscience is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
